ClearPoint Neuro Inc. (CLPT)
NASDAQ: CLPTHealth CareMedical/Dental InstrumentsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
CLPT stock chart
Technical analysisKey statistics
All statistics- Market cap
- $221.49M
- EPS (TTM)
- -$1.21
- Dividend yield
- None
- 52-week range
- 6.85 – 19.63
- Day range
- 6.85 – 7.45
- Volume / Avg
- 1.11M / 701.64K
- Beta
- —
- Shares outstanding
- 32.05M
52-week range
CLPT stock today
ClearPoint Neuro (CLPT) closed at $6.91 on Nov 20, down 5.47% (-$0.40), versus the S&P 500's 3.70% decline. Shares are 64.8% below their 52-week high of $19.63, set on Jun 29, 2026 and 0.9% above the 52-week low of $6.85, near the bottom of the past year's range. CLPT is down 49.5% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 50.0%.
ClearPoint Neuro has posted a net loss over the last twelve months (EPS of -$1.21), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About ClearPoint Neuro
Company profileClearPoint Neuro, Inc., a commercial-stage medical device company, focuses on the development and commercialization of platforms for performing minimally invasive surgical procedures in the brain in the United States. The company offers ClearPoint systems, such as ClearPoint hardware, which includes head fixation frame, computer workstation, and in-room monitor; and ClearPoint disposables, which consist of SmartFrame trajectory device, a hand controller and related accessories, and its SmartFlow Neuro cannula. It also provides ClearPoint software, which guides the physician in surgical planning, device alignment, navigation to the target, and procedure monitoring; ClearPoint Prism Neuro laser therapy system to necrotize or coagulate soft tissue; and IRRAflow system, an active fluid exchange platform.
- Sector
- Health Care
- Industry
- Medical/Dental Instruments
- CEO
- Mr. Joseph Michael Burnett
- Headquarters
- Solana Beach, CA
- Employees
- 172
- Website
- clearpointneuro.com
Financial highlights
Full financialsIn fiscal 2025, ClearPoint Neuro generated $37.0 million in revenue, up 17.8% from fiscal 2024, its 7th consecutive year of revenue growth. ClearPoint Neuro reported a net loss of $25.5 million, compared with a loss of $18.9 million a year earlier. Gross margin was 61.4% (up from 60.9%) and operating margin -65.4%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $36.97M | $31.39M | $23.95M | $20.55M | $16.30M |
| Growth | +17.78% | +31.04% | +16.56% | +26.09% | +27.05% |
| Net income | $-25.54M | $-18.91M | $-22.09M | $-16.43M | $-14.41M |
| EPS (diluted) | $-0.90 | $-0.70 | $-0.90 | $-0.68 | $-0.69 |
Analyst forecast
ForecastConsensus (2 analysts)
none
Avg. price target
$21.50+211.14%
- Strong buy 0
- Buy 2
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Oct 28, 2026
- EPS actual vs est.
- $-0.24 vs $-0.32
- Surprise
- +25.00%
CLPT news
All CLPT news- ClearPoint Neuro, Inc. Amends At-The-Market Equity Offering Sales Agreement to Increase Capacity to $150,000,000Nasdaq
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ClearPoint Neuro, Inc. - CLPTPR Newswire
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ClearPoint Neuro, Inc. - CLPTPR Newswire
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ClearPoint Neuro, Inc. - CLPTPR Newswire
- ClearPoint Neuro (CLPT) Q3 2026 Earnings Call TranscriptNasdaq
- ClearPoint Neuro, Inc. Q3 Loss WidensNasdaq
- ClearPoint Neuro, Inc. Reports Third Quarter 2026 Revenue of $12.1 millionNasdaq
- Idexx Laboratories (IDXX) Reports Next Week: Wall Street Expects Earnings GrowthNasdaqIDXX, CLPT
ClearPoint Neuro peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| PROFProfound Medical Corp. | 6.38 | -3.19% | $233.68M | vs CLPT |
| OSUROraSure Technologies Inc. | 3.46 | -4.16% | $238.90M | vs CLPT |
| KTWOK2 Capital Acquisition Corporation Class A | 10.13 | 0.00% | $203.02M | vs CLPT |
| PDEXPro-Dex Inc. | 63.00 | -0.77% | $201.60M | vs CLPT |
| UTMDUtah Medical Products Inc. | 69.49 | -2.07% | $198.01M | vs CLPT |
| OFIXOrthofix Medical Inc. | 6.07 | -4.26% | $247.41M | vs CLPT |
| SSIISS Innovations International Inc. | 1.27 | -0.78% | $254.86M | vs CLPT |
| ANIKAnika Therapeutics Inc. | 13.23 | -0.38% | $177.22M | vs CLPT |
Indexes, lists and sector
ClearPoint Neuro stock FAQ
What is ClearPoint Neuro's stock price today?
CLPT last traded at $6.91 as of Nov 20, 4:00 PM EST, down 5.47% on the day. Prices are delayed at least 15 minutes.
Does ClearPoint Neuro pay a dividend?
No. ClearPoint Neuro does not currently pay a regular cash dividend.
Who is ClearPoint Neuro's CEO?
Mr. Joseph Michael Burnett is the chief executive officer of ClearPoint Neuro Inc., which has about 172 employees.
Has CLPT ever split its stock?
Yes. The most recent CLPT stock split was a 1-for-40 split on Jul 27, 2016.
What is the CLPT 52-week high?
The 52-week high for CLPT is $19.63 and the 52-week low is $6.85. The stock is currently 64.8% below its high.